PHARMAMAR, S.A
Name of PI: Pablo M. Avilés
Email: paviles@pharmamar.com
PHARMAMAR, S.A.
Pol. Ind. La Mina
Avda. De los Reyes, 1
28770 Colmenar Viejo
Madrid
www.pharmamar.com
Team members working on ITCC-P4 with their position and email address
- Aviles Marin, Pablo Manuel; Manager Non Clinical Toxicology and Pharmacology; paviles@pharmamar.com
- Cataluña del Olmo, Oscar; Technician; ocataluna@pharmamar.com
- Guillen Navarro, Maria Jose; Team Leader; mjguillen@pharmamar.com
- Lopez, Raquel; Technician; rlocana@pharmamar.com
- Nuñez, Praxedes; Technician; pnunes@pharmamar.com
- Palomares, Mandy; Technician; mpalomares@pharmamar.com
- Irigaray, Ana; Regulatory Director; abirigaray@pharmamar.com
- Eibe Guijarro, Carmen; Project Coordination Director; ceibe@pharmamar.com
- García Villaescusa, Elena; Technician; evillaescusa@pharmamar.com
Company presentation
Headquartered in Madrid, PHARMAMAR is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity.
PHARMAMAR explores the seas in search of marine-based compounds which could serve as effective cancer treatments. PHARMAMAR synthesizes chemically any molecule of interest, which eliminates the need to further exploit the source organism.
The company has obtained and marketed the drug Yondelis® (trabectedin) for treating soft tissue sarcoma and relapsed ovarian cancer. PHARMAMAR obtained authorisation to market this drug for STS from the European regulatory authorities in 2007 and for the treatment of relapsed ovarian cancer in 2009; nowadays it also has marketing authorisation recommendation in USA and Japan for STS.
The company has three other compounds in clinical development and other in pre-clinical development for treating other cancers, including breast, lung, solid tumours and multiple myeloma.
PHARMAMAR has significant expertise in the design and conduct of clinical trials as well as in submitting regulatory applications in multiple jurisdictions. Since 1995, it has conducted more than 130 Phase I to Phase III clinical trials in oncology indications, with a total of more than 5,000 patients. Across its portfolio, PHARMAMAR is currently conducting 19 clinical trials. The company manages many of these trials itself.
PHARMAMAR has also a strong commitment to developing orphan drugs: Three of its main drugs have been designated as Orphan Drugs by the European Commission and the FDA for soft tissue sarcoma, ovarian cancer, multiple myeloma and recently for small cell lung cancer (SCLC).
During the last years, PHARMAMAR has implemented a set of patient derived xenografts (PDX) as a part of the in vivo pharmacology characterization for its compounds. Altogether, this effort has led to a panel of ca. 90 PDX of different solid tumors, such as NSCLC, pancreas or colon.